Help with this question

Amy Dyken controller at Pina Pharmaceutical Industries, a public company is currently preparing the calculation for bastcand aliuted earnings per share and the related disclosure for Pina s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Pina Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 11 $1,010,00 8convertible bonds payable 5,050,00 119 bonds payable 5.950,00 Total long-term debt $12.010.00 Shareholders equlty Preferred stock, 5% cumulative $50 par value 105.000 shares authorized 25,250 shares issued and outstanding Common stock, 31 par, 9,800,000 shares authorized, 980,000 shares issued and outstanding Additional pald-in capital Retained earnings Total shareholders' equilty $1,312.50 980,00 3,940,00 5.910,00 $12.142.50 1 2 2 The following transactions have also occurred at Pina Options were granted on July 1, 2019 to purchase 200.000 shares at $15 per share. Although no options were exercised during fiscal year 2020, the average price per common share during fiscal year 2020 was 520 per share Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per 51,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2019. The preferred stock was issued in 2019. There are no preferred dividends in errears; however, preferred dividends were not declared in fiscal year 2020. The 980.000 shares of common stock were outstanding for the entire 2020 fiscal year Net Income for fiscal year 2020 was $1.520,000, and the average Income tax rate is 20% 3 4 5. 6. For the fiscal year ended June 30, 2020, calculate the following for Pina Pharmaceutical Industries. (Round answers to 2 decimal places, eg. $2.45.) (a) Basic earnings per share Basic earnings per share $ 1.49 (b) Olluted earnings per share. Diluted earnings per share A